Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash from Investing Activities over the past 9 years, most recently at $57.1 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $57.1 million for Q4 2025, up 110.53% from a year ago — trailing twelve months through Dec 2025 was $173.9 million (up 130.25% YoY), and the annual figure for FY2025 was $173.9 million, up 130.25%.
  • Cash from Investing Activities for Q4 2025 was $57.1 million at Crinetics Pharmaceuticals, down from $164.8 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for CRNX hit a ceiling of $164.8 million in Q3 2025 and a floor of -$542.1 million in Q4 2024.
  • Median Cash from Investing Activities over the past 5 years was $3.6 million (2022), compared with a mean of -$41.6 million.
  • Peak annual rise in Cash from Investing Activities hit 699.93% in 2025, while the deepest fall reached 27919.09% in 2025.
  • Crinetics Pharmaceuticals' Cash from Investing Activities stood at -$101.8 million in 2021, then surged by 136.2% to $36.9 million in 2022, then tumbled by 336.91% to -$87.3 million in 2023, then plummeted by 520.89% to -$542.1 million in 2024, then soared by 110.53% to $57.1 million in 2025.
  • The last three reported values for Cash from Investing Activities were $57.1 million (Q4 2025), $164.8 million (Q3 2025), and $38.0 million (Q2 2025) per Business Quant data.